PDF
Kurs & Likviditet
Beskrivning
| Land | Norge |
|---|---|
| Lista | OB Match |
| Sektor | Hälsovård |
| Industri | Bioteknik |
NOT FOR DISTRIBUTION OR RELEASE, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA, THE UNITED KINGDOM, AUSTRALIA, CANADA, HONG KONG OR JAPAN, OR ANY OTHER JURISDICTION IN WHICH THE DISTRIBUTION OR RELEASE WOULD BE UNLAWFUL. THIS ANNOUNCEMENT DOES NOT CONSTITUTE AN OFFER OF ANY OF THE SECURITIES DESCRIBED HEREIN.
Oslo, 9 July 2024: Reference is made to the stock exchange announcement published by Circio Holding ASA (the "Company") earlier today, 9 July 2024, regarding the final results of the rights issue (the "Rights Issue").
The following primary insiders and close associates to primary insiders have been allocated new shares and warrants in the Rights Issue, including new shares and warrants as commission for their pre-subscriptions in the Rights Issue:
Erik Digman Wiklund, the CEO of the Company, has been allocated 120,000 new shares and the corresponding number of warrants in the Rights Issue. In addition, Erik Digman Wiklund has been granted 20,400 new shares and the corresponding number of warrants as commission for his pre-subscription in the Rights Issue. As a result, Erik Digman Wiklund, together with his wholly owned company Digman AS, holds 143,733 shares and 140,400 warrants in the Company.
BioPharma Drug Licensing Group SL ("BioPharma"), a close associate of Lubor Gaal, the CFO of the Company, has been allocated 80,000 new shares and the corresponding number of warrants in the Rights Issue. In addition, Biopharma has been granted 13,600 new shares and the corresponding number of warrants as commission for pre-subscription in the Rights Issue. As a result, Lubor Gaal, through his wholly owned company, Biopharma, holds 93,600 shares and 93,600 warrants in the Company.
Damian Marron, the Chairman of the board of directors of the Company, has been allocated 143,604 new shares and the corresponding number of warrants in the Rights Issue. In addition, Damian Marron has been granted 23,800 new shares and the corresponding number of warrants as commission for his pre-subscription in the Rights Issue. As a result, Damian Marron holds 169,256 shares and 167,404 warrants in the Company.
Diane Mary Mellett, board member of the board of directors of the Company, has been allocated 108,000 new shares and the corresponding number of warrants in the Rights Issue. In addition, Diane Mary Mellet has been granted 18,360 new shares and the corresponding number of warrants as commission for her pre-subscription in the Rights Issue. As a result, Diane Mary Mellett holds 130,458 shares and 126,360 warrants in the Company.
Sølen AS, a close associate of Thomas Falck, board member of the board of directors of the Company, has been allocated 80,000 new shares, and the corresponding number of warrants in the Rights Issue. In addition, Sølen AS has been granted 13,600 new shares and the corresponding number of warrants as commission for pre-subscription in the Rights Issue. As a result, Thomas Falck, through his wholly owned company Sølen AS, holds 93,600 shares and 93,600 warrants in the Company.
Robert Forbes Burns, deputy member of the board of directors of the Company, has been allocated 50,000 new shares and the corresponding number of warrants in the Rights Issue. In addition, Robert Forbes Burns has been granted 8,500 new shares and the corresponding number of warrants as commission for his pre-subscription in the Rights Issue. As a result, Robert Forbes Burns holds 68,458 shares and 58,500 warrants in the Company.
Ola Melin, Chief Operating Officer of the Company, has been allocated 40,000 new shares and the corresponding number of warrants in the Rights Issue. In addition, Ola Melin has been granted 6,800 new shares and the corresponding number of warrants as commission for his pre-subscription in the Rights Issue. As a result, Ola Melin holds 48,466 shares and 46,800 warrants in the Company.
Victor Levitsky, Chief Scientific Officer of the Company, has on 8 July 2024 exercised 647 subscription rights, thus entitling him to be allocated 647 offer shares in the Rights Issue. In addition, Victor Levitsky has subscribed for 39,353 offer shares without subscription rights. Victor Levitsky has been allocated a total of 40,000 new shares and the corresponding number of warrants in the Rights Issue. In addition, Victor Levitsky has been granted 6,800 new shares and the corresponding number of warrants as commission for his pre-subscription in the Rights Issue. As a result, Victor Levitsky holds 47,133 shares and 46,800 warrants in the Company.
Thomas Birkballe Hansen, Chief Technology Officer of the Company, has been allocated 40,000 new shares and the corresponding number of warrants in the Rights Issue. In addition, Thomas Birkballe Hansen has been granted 6,800 new shares and the corresponding number of warrants as commission for his pre-subscription in the Rights Issue. As a result, Thomas Birkballe Hansen holds 46,800 shares and 46,800 warrants in the Company.
Please see the attached forms for further details about the transactions.
This information is subject to the disclosure requirements pursuant to article 19 of the EU Market Abuse Regulation and section 5-12 of the Norwegian Securities Trading Act.